It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
In Peru, hepatocellular carcinoma (HCC) arises in young non-cirrhotic patients. Hepatitis B virus (HBV) is suspected to be the prominent etiological agent. We thus performed a comprehensive molecular study of HBV infection in 65 Peruvian HCC patients. Only 51% were considered as persistently infected at the onset. HBV DNA was found by PCR in the tumor and/or matched non-tumor liver tissues in more than 80% of cases (n = 53/65). HBV DNA was significantly more abundant in livers of younger patients than in those of the older ones. We consistently observed low viral DNA burden (0.1–6.5 copies for 100 cells), with viral genomes in younger patients displaying higher proportion of mutations at di-pyrimidines (TpT and CpC, P = 0.006). A drastic activation of multiple DNA repair pathways in tumors of younger patients was observed. Our observations clearly challenge the current vision that associates high HBV DNA load with earlier tumor development. We concluded that in Peru, and maybe in other populations with Americas’ indigenous ancestry, HBV-associated liver tumorigenesis might differ significantly from that generally observed in the rest of the world. Procedures used to screen for HCC development in subjects at risk should be adapted to the local situation.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Ruiz, Eloy 3 ; Cano, Luis 4
; Casavilca, Sandro 5
; Terris, Benoît 6 ; Deharo, Eric 7 ; Dejean, Anne 1 ; Bertani, Stéphane 7
; Pineau, Pascal 1 1 Institut Pasteur, Unité “Organisation Nucléaire et Oncogenèse”, Paris, France
2 Institut Pasteur, Unité “Organisation Nucléaire et Oncogenèse”, Paris, France; Sorbonne Universités, UPMC Université Paris 06, Paris, France
3 Instituto Nacional de Enfermedades Neoplásicas, Departamento de Cirugía en Abdomen, Lima, Peru
4 Université de Rennes 1, INSERM, CNRS, Rennes, France
5 Instituto Nacional de Enfermedades Neoplásicas, Departamento de Patologia, Banco de Tejidos Tumorales, Lima, Peru
6 Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, Service d’Anatomie et Cytologie Pathologiques, Paris, France
7 Université de Toulouse, UPS, UMR152 PHARMADEV, Université Toulouse 3, Toulouse, France




